Trastuzumab has changed the natural history of patients with HER2 positive breast cancer; however, it has documented cardiotoxic effects and the present study showed a prevalence of cardiotoxicity that appeared to be similar to that of the literature [25]. Here, ERBB2 is linked to breast carcinoma.